Technology
LiteVax develops and exploits novel, synthetic carbohydrate derivatives as vaccine adjuvants. These molecules are the outcome of extensive lead finding and optimization of efficacy/toxicity-ratio in large, non-rodent species. Our most advanced product known as ‘LiteVax Adjuvant’ is a synthetic Carbohydrate fatty acid MonoSulphate ester (‘CMS’) immobilized on nano-droplets of a squalane-in-water emulsion.
It elicits unprecedentedly high immune responses with no local or systemic adverse reactions in animals. LiteVax Adjuvant (LVA) is under clinical evaluation with combination influenza virus vaccine in Europe and India.
RELEVANT LITERATURE
Lucille F. van Beek, Christa van der Gaast-de Jongh, Peter Paul Platenburg, Luuk Hilgers, Marien I. de Jonge. Improving the immunogenicity of the pneumococcal conjugate vaccine using a synthetic carbohydrate fatty acid monosulphate squalane-in-water adjuvant, Vaccine 51, 2025, 126893. doi: 10.1016/j.vaccine.2025.126893
D’Onofrio V, Porrez S, Jacobs B, Alhatemi A, De Boever F, Waerlop G, Michels E, Vanni F, Manenti A, Leroux-Roels G, Platenburg PP, Hilgers LATh, Leroux-Roels I. Safety and immunogenicity of a carbohydrate fatty acid monosulphate ester adjuvant combined with a low dose quadrivalent split-virion inactivated influenza vaccine: a randomized, observer-blind, active-controlled, first-in-human, phase 1 study. Vaccines 2024,12,1036. https://doi.org/10.3390/vaccines12091036
Hilgers LAT, Platenburg PPLI, Bajramovic J, Veth J, Sauerwein R, Roeffen W, Pohl M, van Amerongen G, Stittelaar KJ, van den Bosch JF. Carbohydrate fatty acid monosulphate esters are safe and effective adjuvants for humoral responses. Vaccine. 2017 May 31;35(24):3249-3255. doi: 10.1016/j.vaccine.2017.04.055
Platenburg PPLI, Deschamps F, Jung J, Leonard C, Rusconi S, Mohan Kumar SB, Sulaiman SM, de Waal L, Hilgers LAT. Carbohydrate fatty acid monosulphate ester is a potent adjuvant for low-dose seasonal influenza vaccines. Vaccine. 2023 Nov 13;41(47):6980-6990. doi: 10.1016/j.vaccine.2023.10.017
Nanishi E, Borriello F, Seo HS, O’Meara TR, McGrath ME, Saito Y, Chen J, Diray-Arce J, Song K, Xu AZ, Barman S, Menon M, Dong D, Caradonna TM, Feldman J, Hauser BM, Schmidt AG, Baden LR, Ernst RK, Dillen C, Yu J, Chang A, Hilgers L, Platenburg PP, Dhe-Paganon S, Barouch DH, Ozonoff A, Zanoni I, Frieman MB, Dowling DJ, Levy O. Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice. NPJ Vaccines. 2023 Feb 14;8(1):18. doi: 10.1038/s41541-023-00610-4
Aminzadeha A, Hilgers LAT, Platenburg PPLI, Riouc M, Perrotc N, Rossignold C, Cautyc A, Barcc C, Jørgensen R. Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant. Vaccine. 2024 Feb 09. doi: 10.1016/j.vaccine.2024.01.076
Bonam SR, Platenburg PP, Bayry J. Retrospective analysis on the immunopotentiating mechanism of an emulsion-based vaccine adjuvant on human antigen presenting cells. Front Immunol. 2023 Jan 9;13:1086752. doi: 10.3389/fimmu.2022.1086752